Engineered immune cells take aim at stubborn leukemia
NCT ID NCT07538713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a protein called CD33 found on most AML cells. The main goals are to check if the treatment is safe and to see if it can shrink the cancer. About 18 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR-T CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- CAR-T therapy aimed at tough kidney disease in kids — but trial never started
- Promising CAR-T trial for kids with rare vasculitis pulled before start
- Pedal power: could a bike ride supercharge Cancer-Fighting cells?